Download Similar Pharmacokinetics and Pharmacodynamics of Rapid‐acting Insulin Lispro Products SAR342434 and US‐ and EU‐approved Humalog in Subjects with Type 1 Diabetes Books PDF Free

Similar Pharmacokinetics and Pharmacodynamics of Rapid‐acting Insulin Lispro Products SAR342434 and US‐ and EU‐approved Humalog in Subjects with Type 1 Diabetes PDF
By:
Published on 2017 by

Abstract : Aim: To compare the pharmacokinetics (PK) and pharmacodynamics (PD) of 3 rapid‐acting insulin lispro products: SAR342434 solution, United States (US)‐approved Humalog and European Union (EU)‐approved Humalog. Methods: In a single‐centre, randomized, double‐blind, 3‐treatment, 3‐period, 6‐sequence, crossover, euglycaemic clamp study (NCT02273258), adult male subjects with type 1 diabetes were randomized to receive 0.3 U/kg of SAR342434 solution, US‐approved and EU‐approved Humalog under fasted conditions. PK and PD (glucose infusion rate [GIR]) were assessed up to 12 hours. Results: Of the 30 subjects randomized, 28 completed all 3 treatment periods. Mean concentration and GIR vs time profiles were similar for all 3 products. Exposure (INS‐Cmax, INS‐AUClast and INS‐AUC) and activity (GIRmax and GIR‐AUC0‐12h ) of SAR342434, US‐approved and EU‐approved Humalog were similar in all comparisons (point estimates of treatment ratios, 0.95‐1.03 for PK parameters and 1.00‐1.07 for PD parameters), with 90% confidence intervals for the ratios of geometric least squares means within the pre‐specified bioequivalence limit (0.80‐1.25) and no significant differences in time‐related parameters. Within‐subject variability of exposure and activity was low across the 3 clamps, indicating high day‐to‐day reproducibility in clamp performance, irrespective of the individual product. Adverse events were similar for all 3 products. No safety concerns were noted in vital signs or in laboratory and electrocardiogram data. Conclusions: The results of this study demonstrate similarity in insulin lispro exposure profiles and PD activity of SAR342434 solution to both US‐ and EU‐approved Humalog, and between both US‐ and EU‐approved Humalog, supporting the use of SAR342434 solution for injection as a follow‐on product.

This Book was ranked at 14 by Google Books for keyword Pharmacodynamics.

Book ID of Similar Pharmacokinetics and Pharmacodynamics of Rapid‐acting Insulin Lispro Products SAR342434 and US‐ and EU‐approved Humalog in Subjects with Type 1 Diabetes's Books is Fd2ztAEACAAJ, Book which was written by have ETAG "EnrAz+uxVNY"

Book which was published by since 2017 have ISBNs, ISBN 13 Code is and ISBN 10 Code is

Reading Mode in Text Status is false and Reading Mode in Image Status is false

Book which have " Pages" is Printed at BOOK under Category

Book was written in en

eBook Version Availability Status at PDF is falseand in ePub is false

Book Preview

Download Similar Pharmacokinetics and Pharmacodynamics of Rapid‐acting Insulin Lispro Products SAR342434 and US‐ and EU‐approved Humalog in Subjects with Type 1 Diabetes PDF Free

Download Similar Pharmacokinetics and Pharmacodynamics of Rapid‐acting Insulin Lispro Products SAR342434 and US‐ and EU‐approved Humalog in Subjects with Type 1 Diabetes Books Free

Download Similar Pharmacokinetics and Pharmacodynamics of Rapid‐acting Insulin Lispro Products SAR342434 and US‐ and EU‐approved Humalog in Subjects with Type 1 Diabetes Free

Download Similar Pharmacokinetics and Pharmacodynamics of Rapid‐acting Insulin Lispro Products SAR342434 and US‐ and EU‐approved Humalog in Subjects with Type 1 Diabetes PDF

Download Similar Pharmacokinetics and Pharmacodynamics of Rapid‐acting Insulin Lispro Products SAR342434 and US‐ and EU‐approved Humalog in Subjects with Type 1 Diabetes Books